This week in sickle cell news September 28th to the 4th of October

By Sean Marshall
​An article published this week has stated that “Mast Therapeutics shows promise regarding sickle cell treatment as mentioned by opinion leader.” This article featured on Street Wis Journal one of Richmond Vermont’s business trading news organization has reported that Roth Capital health care annalist Michael Higgins has “shed some light regarding the feasibility and potential short and mid-term prospects of Mast Therapeutics.”

Mast Therapeutics is a San-Diego based biopharmaceutical company. At least that's what it says on their website. The company itself specializes in treating various disease but as of recently they have been attempting to aid in the treatment and possible curing of sickle cell disease.

What is so important about Mass Therapeutics right now is that they are teaming up with it was a the Rutgers Cancer Institute of New Jersey Higgins which has “been treating around 450 patients who have sickle cell anemia.”

The reason for the treatment is that the area in recent years has seen an increase in sickle cell anemia. In fact stats given were around 70%. With the combined efforts of a big drug company and a Rutgers Cancer Institute there should be a positive outcome. Especially since Mast Theraputics stocks have risen because of the announcement.

The article since it is primary business focused did mention that this has mainly been done in an attempt to bring up stick to 3 dollars a share. Oddly this could have a beneficially outcome. If it does increase to the desired affect it shows that a cure for sickle cell disease is profitable.

Perhaps other companies will follow Mast Therapeutics footsteps if all goes as planned. But what is really important is the people who lies should hopefully be improved by the overall research. Especially those in New Jersey.

The original article can be found in the link: http://www.streetwisejournal.com/mast-therapeutics-shows-promise-regarding-sickle-cell-treatment-as-mentioned-by-opinion-leader/11426/

If you have any comments questions or concerns email us at [email protected]